Get the Stockscreener App
6.91
1.14%
-0.08
After Hours:
6.99
0.08
+1.16%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc Stock (ALT) Latest News
H.C. Wainwright maintains Buy on Altimmune stock, $12 target - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
BlackRock, Inc.'s Strategic Acquisition of Altimmune Inc Shares - GuruFocus.com
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns - Yahoo Finance
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average PT from Analysts - MarketBeat
Exchange Traded Concepts LLC Cuts Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
HC Wainwright Weighs in on Altimmune FY2029 Earnings - MarketBeat
JPMorgan Chase & Co. Decreases Holdings in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Sprout Social, Altimmune, Equinix, and Globe Life - GlobeNewswire
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages - EIN News
(ALT) Technical Pivots with Risk Controls - Stock Traders Daily
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Altimmune Management Reveals Strategic Roadmap at Major Biotech Conference - StockTitan
HC Wainwright Forecasts Altimmune FY2029 Earnings - MarketBeat
Altimmune spikes after presenting data for obesity drug - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com UK
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune's (ALT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Long Term Trading Analysis for (ALT) - Stock Traders Daily
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Altimmune stock at Buy on pemvidutide potential - Investing.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Yahoo Finance
Altimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street Corp - MarketBeat
Altimmune (NASDAQ:ALT) Stock Price Down 4.6%Should You Sell? - MarketBeat
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading Up 4.7%Here's Why - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):